Wave Life Sciences (WVE) Net Margin (2015 - 2026)
Wave Life Sciences' (WVE) quarterly Net Margin came in at 3052.6% in Q2 2026, down 247243.0% YoY from N/an in Q2 2025, and down 4375.39% on a QoQ basis from 68.21% in Q1 2026.
Powered by 
Analysis
Wave Life Sciences (WVE) Net Margin (2015 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 12 years of Net Margin data on file, last reported at 3052.6% in Q2 2026.
- Quarterly Net Margin fell 247243.0% year-over-year to 3052.6% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 346.75% (down 8754.0% YoY) and the FY2025 annual result came in at 478.33%, down 38876.0% from the prior year.
- Net Margin declined to 3052.6% in Q2 2026, from 68.21% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 14.78% in Q3 2023 to a low of 13685.61% in Q3 2022.
- A 5-year average of 2526.14% and a median of 381.32% in 2025 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin tumbled 1366851 bps — and 2023, when it jumped 1370040 bps.
- Tracing WVE's Net Margin over 5 years: stood at 3527.76% in 2022, then jumped by 98 bps to 56.03% in 2023, then sank by 198 bps to 167.19% in 2024, then sank by 247 bps to 580.17% in 2025, then sank by 426 bps to 3052.6% in 2026.
- The last three Net Margin figures came in at 3052.6% (Q2 2026), 68.21% (Q1 2026), and 580.17% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Wave Life Sciences | 994.54 Mn | 626.53 Mn | - | -3,052.60% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,052.60% |
| Mar 31, 2026 | -68.21% |
| Dec 31, 2025 | -308.37% |
| Sep 30, 2025 | -707.83% |
| Jun 30, 2025 | -580.17% |
| Mar 31, 2025 | -510.93% |
| Dec 31, 2024 | 34.93% |
| Sep 30, 2024 | -804.85% |
| Jun 30, 2024 | -167.19% |
| Mar 31, 2024 | -251.70% |
| Dec 31, 2023 | -56.03% |
| Sep 30, 2023 | 14.78% |
| Jun 30, 2023 | -95.47% |
| Mar 31, 2023 | -211.97% |
| Dec 31, 2022 | -3,527.76% |
| Sep 30, 2022 | -13,685.61% |
| Jun 30, 2022 | -11,012.27% |
| Mar 31, 2022 | -2,160.80% |
| Dec 31, 2021 | -1,970.82% |
| Sep 30, 2021 | -17.10% |